Brentuximab Vedotin

From Anvita Health Wiki

Contents 1 Structure 2 Indications 3 Dosage 4 Adverse-effects 5 Mechanism-of-action 6 More General Terms 7 References

Structure

• approximate molecular weight of 153 kDa
• the drug consists of 3 components

• chimeric IgG1 antibody cAC10, specific for human CD30
• microtubule disrupting agent MMAE
• a protease-cleavable linker that covalently attaches MMAE to cAC10

Indications

• treatment of relapsed or refractory Hodgkin's lymphoma
• systemic anaplastic large cell lymphoma with treatment failure

Dosage

• 1.8 mg/kg infused over 30 minutes every 3 weeks
• maximum of 16 cycles
  

• Lyophilyzed powder in single use vials

• reconstituted with 10.5 mL of sterile water yields brentuximab vedotin 5 mg/mL, pH=6.6

Adverse-effects

• hematologic

• neutropenia
• anemia
• thrombocytopenia
• lymphadenopathy

• neurologic

• peripheral neuropathy
• headache
• dizziness
• progressive multifocal leukoencephalopathy [3]

• general

• fatigue
• pyrexia
• chills
• night sweats
• peripheral edema
• anorexia
• weight loss

• infections

• upper respiratory tract infection

• gastrointestinal

• nausea/vomiting
• diarrhea
• abdominal pain
• constipation

• skin

• rash
• pruritus
• alopecia
• dry skin

• respiratory

• cough
• dyspnea
• oropharyngeal
• pulmonary toxicity

• musculoskeletal

• arthralgia
• myalgia
• back pain
• pain in extremity
• muscle spasms

• psychiatric

• insomnia
• anxiety

Mechanism-of-action

• antibody-drug conjugate that combines the monoclonal antibody brentuximab & the antimitotic agent monomethyl auristatin (vedotin), thus targeting CD30 receptors on tumor cells before release of the toxic chemotherapeutic agent

More General Terms

• antineoplastic agent (chemotherapeutic agent)

References

1. Waknine Y Medscape Oncology FDA Approves Brentuximab for Refractory Lymphomas [1]
2. National Cancer Institute FDA Approval for Brentuximab Vedotin [2]
3. FDA MedWatch: 01/13/2012 Adcetris (brentuximab vedotin): Drug Safety Communication - Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity [3]
4. Adcetris [4]

brentuximab vedotin (Adcetris)